I've heard that some big pharma cos. often (not always!) pay somewhere around a "fair price" on buyouts, so the fact that biotechs are in the toilet the past many weeks should not make too much difference on a BO price for RLYP. As Adam Feuerstein and others have said, RLYP's Veltassa is "at least as good as ZSPH's ZS-9" and ZSPH was bought out by AZN for $2.7billion with no guarantee of FDA approval or lack of a black-box warning.
So... given that RLYP
--has already been approved and
--has released robust (large sample) DDI results showing zero interaction for 9 or 12 drugs studied and less than 3 hours ddi for the other 3 drugs (i.e., good chance RLYP will have that bb warning label softened or dropped by FDA),
--and adding RLYP's clinically well-known effect of lowering blood pressure,
--and adding the greater liabilities for ZS-9 that have emerged since the BO of ZSPH (excess sodium, likelihood of higher # of adverse events in their trials, etc.)....
... all points to a deserved valuation higher than ZSPH's $2.7Bn.
That puts a fair BO price for RLYP up around $68-$70-$75.
Frankly I think most shareholders (including myself) would be quite happy to get a BO for $50-$55 and then try to make up the "lost value" via gains elsewhere on another stock's rebound out of this bear mkt.
